Latest Breaking News On - Shintaro nishimura - Page 1 : comparemela.com

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites

MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces.

United kingdomUnited statesKyahn williamsonBayer crossColin haywardShintaro nishimuraAustralian securities exchangeOrion corporationDrug administrationCorporate communicationsTelix pharmaceuticalsAustralian therapeutic goods administrationTelix pharmaceuticals japanHealth canadaTelix pharmaceuticals limitedEuropean union

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites
macaubusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from macaubusiness.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomKyahn williamsonColin haywardShintaro nishimuraBayer crossHealth canadaTelix pharmaceuticals limitedTelix pharmaceuticalsEuropean unionOrion corporationCorporate communicationsDrug administrationTelix pharmaceuticals japanBayer agAustralian securities exchange

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites

MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Phase III ARASTEP study (ClinicalTrials.gov Identifier: NCT05794906). This global study is.

United kingdomUnited statesColin haywardShintaro nishimuraKyahn williamsonBayer crossBayer agOrion corporationPrnewswire telix pharmaceuticals limitedHealth canadaAustralian therapeutic goods administrationDrug administrationTelix pharmaceuticalsEuropean unionAustralian securities exchangeTelix pharmaceuticals japan

Japanese Prostate Cancer Imaging Trial Meets Study

MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration.

United statesToshinori murayamaShintaro nishimuraStewart holmstromUnitedstatesandmaynotbeofferedorsoldwithintheunited statesChristian behrenbruchTelix pharmaceuticalsKanazawa universityDrug administrationAustralian securities exchangeAustralian therapeutic goods administrationCorporate communicationsTelix pharmaceuticals limitedTelix pharmaceuticals japanKanazawa university hospitalDepartment of clinical development

Japanese Prostate Cancer Imaging Trial Meets Study Objectives

08.02.2022 - MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) - Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that the Phase I clinical study of its investigational .

United statesToshinori murayamaShintaro nishimuraStewart holmstromUnitedstatesandmaynotbeofferedorsoldwithintheunited statesChristian behrenbruchAbouttelix pharmaceuticalsTelix pharmaceuticalsKanazawa universityDrug administrationAustralian securities exchangeAustralian therapeutic goods administrationCorporate communicationsTelix pharmaceuticals japanKanazawa university hospitalDepartment of clinical development